{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:53:59Z","timestamp":1780520039536,"version":"3.54.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T00:00:00Z","timestamp":1493251200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00467-017-3675-7","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T08:36:36Z","timestamp":1493282196000},"page":"1103-1108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oral paricalcitol: expanding therapeutic options for pediatric chronic kidney disease patients"],"prefix":"10.1007","volume":"32","author":[{"given":"Michael","family":"Freundlich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0984-3771","authenticated-orcid":false,"given":"Carolyn L.","family":"Abitbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,27]]},"reference":[{"key":"3675_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-017-3579-6","author":"NJA Webb","year":"2017","unstructured":"Webb NJA, Lerner G, Warady BA, Dell KM, Greenbaum LA, Ariceta G, Hoppe B, Linde P, Lee H-J, Eldred A, Dufek MB (2017) Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease. Pediatr Nephrol. doi: 10.1007\/s00467-017-3579-6","journal-title":"Pediatr Nephrol"},{"key":"3675_CR2","unstructured":"National Kidney Foundation (2005) K\/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46[4 Suppl 1]:S1\u2013103"},{"key":"3675_CR3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nrneph.2015.219","volume":"12","author":"JF Bertram","year":"2016","unstructured":"Bertram JF, Goldstein SL, Pape L, Schaefer F, Shroff RC, Warady BA (2016) Kidney disease in children: latest advances and remaining challenges. Nat Rev Nephrol 12:182\u2013191","journal-title":"Nat Rev Nephrol"},{"key":"3675_CR4","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS, Guti\u00e9rrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370\u20131378 Erratum in: Kidney Int 82:498","journal-title":"Kidney Int"},{"key":"3675_CR5","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s004670000355","volume":"14","author":"J Silver","year":"2000","unstructured":"Silver J, Kilav R, Sela-Brown A, Naveh-Many T (2000) Molecular mechanisms of secondary hyperparathyroidism. Pediatr Nephrol 14:626\u2013628","journal-title":"Pediatr Nephrol"},{"key":"3675_CR6","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/ki.1990.293","volume":"38","author":"DS Milliner","year":"1990","unstructured":"Milliner DS, Zinsmeister AR, Lieberman E, Landing B (1990) Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 38:931\u2013936","journal-title":"Kidney Int"},{"key":"3675_CR7","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","volume":"342","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478\u20131483","journal-title":"N Engl J Med"},{"key":"3675_CR8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s004670000352","volume":"14","author":"IB Salusky","year":"2000","unstructured":"Salusky IB, Goodman WG, Kuizon BD (2000) Implications of intermittent calcitriol therapy on growth and secondary hyperparathyroidism. Pediatr Nephrol 14:641\u2013645","journal-title":"Pediatr Nephrol"},{"key":"3675_CR9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1067\/mlc.2002.122819","volume":"139","author":"AJ Brown","year":"2002","unstructured":"Brown AJ, Finch J, Slatopolsky E (2002) Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med 139:279\u2013284","journal-title":"J Lab Clin Med"},{"key":"3675_CR10","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1053\/ajkd.2002.36899","volume":"40","author":"DW Coyne","year":"2002","unstructured":"Coyne DW, Grieff M, Ahya SN, Giles K, Norwood K, Slatopolsky E (2002) Differential effects of acute administration of 19-nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 40:1283\u20131288","journal-title":"Am J Kidney Dis"},{"key":"3675_CR11","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","volume":"9","author":"KJ Martin","year":"1998","unstructured":"Martin KJ, Gonz\u00e1lez EA, Gellens M, Hamm LL, Abboud H, Lindberg J (1998) 19-nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9:1427\u20131432","journal-title":"J Am Soc Nephrol"},{"key":"3675_CR12","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00467-004-1792-6","volume":"20","author":"LA Greenbaum","year":"2005","unstructured":"Greenbaum LA, Grenda R, Qiu P, Restaino I, Wojtak A, Paredes A, Benador N, Melnick JZ, Williams LA, Salusky IB (2005) Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr Nephrol 20:622\u2013630","journal-title":"Pediatr Nephrol"},{"key":"3675_CR13","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1007\/s00467-006-0204-5","volume":"21","author":"W Seeherunvong","year":"2006","unstructured":"Seeherunvong W, Nwobi O, Abitbol CL, Chandar J, Strauss J, Zilleruelo G (2006) Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol 21:1434\u20131439","journal-title":"Pediatr Nephrol"},{"key":"3675_CR14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","volume":"71","author":"A Levin","year":"2007","unstructured":"Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31\u201338 Erratum in: Kidney Int. 2009; 75:1237","journal-title":"Kidney Int"},{"key":"3675_CR15","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.2215\/CJN.02110216","volume":"11","author":"AA Portale","year":"2016","unstructured":"Portale AA, Wolf MS, Messinger S, Perwad F, J\u00fcppner H, Warady BA, Furth SL, Salusky IB (2016) Fibroblast growth factor 23 and risk of CKD progression in children. Clin J Am Soc Nephrol 11:1989\u20131998","journal-title":"Clin J Am Soc Nephrol"},{"key":"3675_CR16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","volume":"47","author":"D Coyne","year":"2006","unstructured":"Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM (2006) Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47:263\u2013276","journal-title":"Am J Kidney Dis"},{"key":"3675_CR17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2215\/CJN.03000311","volume":"7","author":"J Cheng","year":"2012","unstructured":"Cheng J, Zhang W, Zhang X, Li X, Chen J (2012) Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 7:391\u2013400 Erratum in: Clin J Am Soc Nephrol 2012; 7:1053","journal-title":"Clin J Am Soc Nephrol"},{"key":"3675_CR18","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1053\/j.ajkd.2011.08.001","volume":"58","author":"K Uhlig","year":"2011","unstructured":"Uhlig K (2011) What should a guideline panel do when evidence is inconclusive? The case of treatments for CKD-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 58:872\u2013875","journal-title":"Am J Kidney Dis"},{"key":"3675_CR19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00467-007-0684-y","volume":"23","author":"L Rees","year":"2008","unstructured":"Rees L (2008) What parathyroid hormone levels should we aim for in children with stage 5 chronic kidney disease; what is the evidence? Pediatr Nephrol 23:179\u2013184","journal-title":"Pediatr Nephrol"},{"key":"3675_CR20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00467-005-2082-7","volume":"21","author":"G Klaus","year":"2006","unstructured":"Klaus G, Watson A, Edefonti A, Fischbach M, R\u00f6nnholm K, Schaefer F, Simkova E, Stefanidis CJ, Strazdins V, Vande Walle J, Schr\u00f6der C, Zurowska A, Ekim M, European Paediatric Dialysis Working Group (EPDWG) (2006) Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 21:151\u2013159","journal-title":"Pediatr Nephrol"},{"key":"3675_CR21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00467-012-2270-1","volume":"28","author":"D Haffner","year":"2013","unstructured":"Haffner D, Schaefer F (2013) Searching the optimal PTH target range in children undergoing peritoneal dialysis: new insights from international cohort studies. Pediatr Nephrol 28:537\u2013545","journal-title":"Pediatr Nephrol"},{"key":"3675_CR22","doi-asserted-by":"crossref","unstructured":"Hahn D, Hodson EM, Craig J (2015) Interventions for metabolic bone disease in children with chronic kidney disease. Cochrane Database Syst Rev 12:CD008327","DOI":"10.1002\/14651858.CD008327.pub2"},{"issue":"5 Suppl 5","key":"3675_CR23","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1053\/ajkd.2001.28112","volume":"38","author":"KJ Martin","year":"2001","unstructured":"Martin KJ, Gonz\u00e1lez E, Lindberg JS, Taccetta C, Amdahl M, Malhotra K, Llach F (2001) Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Am J Kidney Dis 38[5 Suppl 5]:S57\u2013S63","journal-title":"Am J Kidney Dis"},{"key":"3675_CR24","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","volume":"376","author":"D Zeeuw de","year":"2010","unstructured":"de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376:1543\u20131551","journal-title":"Lancet"},{"key":"3675_CR25","first-page":"2253","volume":"307","author":"R Thadhani","year":"2012","unstructured":"Thadhani R, Tamez H, Solomon SD (2012) Vitamin D therapy and cardiac function in chronic kidney disease-reply. JAMA 307:2253","journal-title":"JAMA"},{"key":"3675_CR26","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/ki.2011.207","volume":"80","author":"R Agarwal","year":"2011","unstructured":"Agarwal R, Hynson JE, Hecht TJ, Light RP, Sinha AD (2011) Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate. Kidney Int 80:1073\u20131079","journal-title":"Kidney Int"},{"key":"3675_CR27","doi-asserted-by":"crossref","first-page":"e0147347","DOI":"10.1371\/journal.pone.0147347","volume":"11","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Li M, Zhang T, Chen J (2016) Effect of vitamin D receptor activators on glomerular filtration rate: a meta-analysis and systematic review. PLoS One 11:e0147347","journal-title":"PLoS One"},{"key":"3675_CR28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00467-016-3373-x","volume":"32","author":"H Pottel","year":"2017","unstructured":"Pottel H (2017) Measuring and estimating glomerular filtration rate in children. Pediatr Nephrol 32:249\u2013263","journal-title":"Pediatr Nephrol"},{"key":"3675_CR29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MNH.0b013e32834de4ee","volume":"21","author":"YC Li","year":"2012","unstructured":"Li YC (2012) Vitamin D: roles in renal and cardiovascular protection. Curr Opin Nephrol Hypertens 21:72\u201379","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"3675_CR30","doi-asserted-by":"crossref","first-page":"622","DOI":"10.2353\/ajpath.2010.091292","volume":"177","author":"J Kong","year":"2010","unstructured":"Kong J, Kim GH, Wei M, Sun T, Li G, Liu SQ, Li X, Bhan I, Zhao Q, Thadhani R, Li YC (2010) Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am J Pathol 177:622\u2013631","journal-title":"Am J Pathol"},{"key":"3675_CR31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI0215219","volume":"110","author":"YC Li","year":"2002","unstructured":"Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP (2002) 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229\u2013238","journal-title":"J Clin Invest"},{"key":"3675_CR32","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/ki.2008.408","volume":"74","author":"M Freundlich","year":"2008","unstructured":"Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-Iturbe B (2008) Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 74:1394\u20131402","journal-title":"Kidney Int"},{"key":"3675_CR33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.ki.5000045","volume":"69","author":"DL Andress","year":"2006","unstructured":"Andress DL (2006) Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 69:33\u201343","journal-title":"Kidney Int"},{"key":"3675_CR34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ppedcard.2015.11.001","volume":"41","author":"M Freundlich","year":"2016","unstructured":"Freundlich M, Lipshultz SE, Filler G (2016) Chronic kidney disease and cardiac morbidity\u2014what are the possible links? Prog Pediatr Cardiol 41:89\u201395","journal-title":"Prog Pediatr Cardiol"},{"key":"3675_CR35","doi-asserted-by":"crossref","first-page":"16810","DOI":"10.1073\/pnas.0611202104","volume":"104","author":"N Bodyak","year":"2007","unstructured":"Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM (2007) Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in dahl salt-sensitive animals. Proc Natl Acad Sci USA 104:16810\u201316815","journal-title":"Proc Natl Acad Sci USA"},{"key":"3675_CR36","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/ajh\/hpt177","volume":"27","author":"M Freundlich","year":"2014","unstructured":"Freundlich M, Li YC, Quiroz Y, Bravo Y, Seeherunvong W, Faul C, Weisinger JR, Rodriguez-Iturbe B (2014) Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats. Am J Hypertens 27:720\u2013726","journal-title":"Am J Hypertens"},{"key":"3675_CR37","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","volume":"349","author":"M Teng","year":"2003","unstructured":"Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446\u2013456","journal-title":"N Engl J Med"},{"key":"3675_CR38","doi-asserted-by":"crossref","first-page":"c21","DOI":"10.1159\/000088295","volume":"102","author":"HW Kim","year":"2006","unstructured":"Kim HW, Park CW, Shin YS, Kim YS, Shin SJ, Kim YS, Choi EJ, Chang YS, Bang BK (2006) Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract 102:c21\u2013c29","journal-title":"Nephron Clin Pract"},{"key":"3675_CR39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000350579","volume":"36","author":"A Bellasi","year":"2013","unstructured":"Bellasi A, Galassi A, Salvi P, Cozzolino M (2013) Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice. Blood Purif 36:12\u201316","journal-title":"Blood Purif"},{"key":"3675_CR40","first-page":"149","volume":"8","author":"D Duplancic","year":"2013","unstructured":"Duplancic D, Cesarik M, Poljak NK, Radman M, Kovacic V, Radic J, Rogosic V (2013) The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection. Clin Interv Aging 8:149\u2013156","journal-title":"Clin Interv Aging"},{"key":"3675_CR41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2013010103","volume":"25","author":"AY Wang","year":"2014","unstructured":"Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, Lo G, Lai KN, Lo WK, Lam CW, Yu CM (2014) Effect of paricalcitol on left ventricular mass and function in CKD\u2014the OPERA trial. J Am Soc Nephrol 25:175\u2013186","journal-title":"J Am Soc Nephrol"},{"key":"3675_CR42","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ahj.2012.09.018","volume":"164","author":"H Tamez","year":"2012","unstructured":"Tamez H, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, Pritchett Y, Chang Y, Agarwal R, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Singh B, Zehnder D, Pachika A, Manning WJ, Shah A, Solomon SD, Thadhani R (2012) Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J 164:902\u2013909.e2","journal-title":"Am Heart J"},{"key":"3675_CR43","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1007\/s00467-011-2071-y","volume":"27","author":"R Shroff","year":"2012","unstructured":"Shroff R, Wan M, Rees L (2012) Can vitamin D slow down the progression of chronic kidney disease? Pediatr Nephrol 27:2167\u20132173","journal-title":"Pediatr Nephrol"},{"key":"3675_CR44","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s00246-012-0489-z","volume":"34","author":"AR Patange","year":"2013","unstructured":"Patange AR, Valentini RP, Gothe MP, Du W, Pettersen MD (2013) Vitamin D deficiency is associated with increased left ventricular mass and diastolic dysfunction in children with chronic kidney disease. Pediatr Cardiol 34:536\u2013542","journal-title":"Pediatr Cardiol"},{"key":"3675_CR45","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00467-012-2224-7","volume":"27","author":"W Seeherunvong","year":"2012","unstructured":"Seeherunvong W, Abitbol CL, Chandar J, Rusconi P, Zilleruelo GE, Freundlich M (2012) Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. Pediatr Nephrol 27:2129\u20132136","journal-title":"Pediatr Nephrol"},{"key":"3675_CR46","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1681\/ASN.2011111115","volume":"23","author":"MM Mitsnefes","year":"2012","unstructured":"Mitsnefes MM (2012) Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 23:578\u2013585","journal-title":"J Am Soc Nephrol"},{"key":"3675_CR47","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2215\/CJN.08420811","volume":"8","author":"MC Matteucci","year":"2013","unstructured":"Matteucci MC, Chinali M, Rinelli G, W\u00fchl E, Zurowska A, Charbit M, Pongiglione G, Schaefer F, ESCAPE Trial Group (2013) Change in cardiac geometry and function in CKD children during strict BP control: a randomized study. Clin J Am Soc Nephrol 8:203\u2013210","journal-title":"Clin J Am Soc Nephrol"},{"key":"3675_CR48","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Guti\u00e9rrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393\u20134408","journal-title":"J Clin Invest"},{"key":"3675_CR49","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1681\/ASN.2006091028","volume":"18","author":"M Mizobuchi","year":"2007","unstructured":"Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, Slatopolsky E (2007) Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 18:1796\u20131806","journal-title":"J Am Soc Nephrol"},{"key":"3675_CR50","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ajpath.2015.11.015","volume":"186","author":"R Sonneveld","year":"2015","unstructured":"Sonneveld R, Hoenderop JG, Stavenuiter AW, Ferrantelli E, Baltissen MP, Dijkman HB, Florquin S, Rops AL, Wetzels JF, Berden JH, van der Vlag J, Nijenhuis T (2015) 1,25-vitamin D3 deficiency induces albuminuria. Am J Pathol 186:794\u2013804","journal-title":"Am J Pathol"},{"key":"3675_CR51","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1111\/j.1523-1755.2005.00755.x","volume":"68","author":"R Agarwal","year":"2005","unstructured":"Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68:2823\u20132828","journal-title":"Kidney Int"},{"key":"3675_CR52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/HYPERTENSIONAHA.108.113159","volume":"52","author":"P Alborzi","year":"2008","unstructured":"Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R (2008) Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 52:249\u2013255","journal-title":"Hypertension"},{"key":"3675_CR53","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.ajkd.2009.04.036","volume":"54","author":"S Fishbane","year":"2009","unstructured":"Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N (2009) Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 54:647\u2013652","journal-title":"Am J Kidney Dis"},{"key":"3675_CR54","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1681\/ASN.2013030203","volume":"24","author":"MH Borst de","year":"2013","unstructured":"de Borst MH, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJ (2013) Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol 24:1863\u20131871","journal-title":"J Am Soc Nephrol"},{"key":"3675_CR55","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2215\/CJN.01780408","volume":"4","author":"CS Wong","year":"2009","unstructured":"Wong CS, Pierce CB, Cole SR, Warady BA, Mak RH, Benador NM, Kaskel F, Furth SL, Schwartz GJ, CKiD Investigators (2009) Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. Clin J Am Soc Nephrol 4:812\u2013819","journal-title":"Clin J Am Soc Nephrol"},{"key":"3675_CR56","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1046\/j.1523-1755.2003.00033.x","volume":"63","author":"P Ruggenenti","year":"2003","unstructured":"Ruggenenti P, Perna A, Remuzzi G, GISEN Group Investigators (2003) Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 63:2254\u20132261","journal-title":"Kidney Int"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-017-3675-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-017-3675-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-017-3675-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T23:59:18Z","timestamp":1658966358000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-017-3675-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,27]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["3675"],"URL":"https:\/\/doi.org\/10.1007\/s00467-017-3675-7","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,27]]}}}